Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

68 results about "Testicular cancer" patented technology

Cancer that develops in the testicles, a male organ that produce sex hormones and sperm for reproduction.

Biological compositions and methods for treatment of testicular cancer

The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with testicular cancer. The biological compositions can be used to retard the growth of testicular cancer cells and / or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.
Owner:ULTRA BIOTECH

Prmt1 for target genes of cancer therapy and diagnosis

Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.
Owner:ONCOTHERAPY SCI INC

MORC gene compositions and methods of use

Disclosed are compositions and methods comprising a novel mammalian gene, designated MORC, that is expressed in male germ cells. Also disclosed are polynucleotide compositions comprising a MORC gene from human and murine sources, and polypeptides encoded by these nucleic acid sequences. Methods for preparing MORC polypeptides, transformed host cells, and antibodies reactive with MORC polypeptides are also provided. In certain embodiments, the invention describes methods for diagnosing and treating infertility or testicular cancer, as well as methods for identifying MORC-related polynucleotide and polypeptide compositions.< / PTEXT>
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Soluble Nanoparticles as Delivery Systems for Prodrugs

Compounds and methods are disclosed in which a prodrug can be delivered in an elevated oxidative state to cells by means of graphitic nanoparticles to which the prodrug is attached by a hydrophilic polymer and which have been made soluble by a hydrophilic polymer, such as PEG. The graphitic nanoparticle may be a single walled carbon nanotube (SWNT). The prodrug may be a DNA-binding metal-based drug. Exemplified is a platinum(IV) complex c,c,t-[Pt(NH3)2Cl2(OEt)(O2CCH2CH2CO2H)], which is nearly nontoxic to testicular cancer cells, but displays a significantly enhanced cytotoxicity profile when attached to the surface of amine-functionalized soluble SWNTs. An amine functionality on the hydrophilic polymer may be used to link the prodrug.
Owner:MASSACHUSETTS INST OF TECH +1

Deuterium-Enriched Pyrimidine Compounds and Derivatives

ActiveUS20130040957A1Prevent proliferationBiocideSenses disorderDiseaseMalignant carcinoid tumors
The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.
Owner:DHANOA DALJIT SINGH

Antibodies, pharmaceutical compositions and methods

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and / or brain tumor.
Owner:OBI PHARMA

Immunogenic peptides and methods of use

The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.
Owner:UNITED STATES OF AMERICA

Compounds and methods for modulation of estrogen receptors

InactiveUS20050004360A1BiocideSenses disorderEccentric hypertrophyHormonal imbalance
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-β over ER-α. Methods are disclosed for modulating ER-β in cell and / or tissues expressing the same, including cells and / or tissue that preferentially express ER-β. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.
Owner:SIGNAL PHARMA LLC

Glutathione derivative and anti-tumor medical application thereof

The invention belongs to the technical field of medicaments, and discloses anti-tumor medicaments of S-(bromo-acetamido-alanyl-methyl) glutathione and S-(bromo-acetamido-butaminoacyl-methyl) glutathione. The compound reacts with aldoketomutase I in a covalent bond mode so that the aldoketomutase I losses the activity irreversibly. The compound has good development and application prospects in theaspects of medicaments for treating the malignant tumors of prostate cancer, lung cancer, intestinal cancer, testicular cancer, leukemia, mammary cancer, skin cancer and the like.
Owner:SHANGHAI YUANNONG MEDICAL SCI

VHZ for diagnosis and treatment of cancers

We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer in an individual selected from the group consisting of: colon cancer, lung cancer, squamous cell carcinoma including lip, larynx, vulva, cervix and penis cancer, pancreatic cancer, brain cancer, oesophageal cancer, stomach cancer, bladder cancer, kidney cancer, skin cancer, ovary cancer, prostate cancer and testicular cancer. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of such a cancer. The anti-VHZ agent may comprise SEQ ID NO:4 or SEQ ID NO: 5, or both.
Owner:AGENCY FOR SCI TECH & RES

(Spirocyclylamido)aminothiophene compounds

InactiveUS20060063791A1BiocideOrganic chemistryAbnormal tissue growthAdenoid cystic carcinoma
Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, R1, X and Y are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis / mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer / T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.
Owner:OSI PHARMA INC

Application of micromolecular nucleic acid miR-302 for treating or preventing testicular cancer

The invention relates to endogenic non-coding microRNA (micro Ribonucleic Acid), a medicine composition containing the microRNA, and new application of the medicine composition for treating or preventing the testicular cancer. According to the invention, the microRNA belonging to the family member (miR-302) of the microRNA-302 and platinum-type anti-tumour medicines are utilized jointly, so that the treatment effect of the platinum-type anti-tumour medicines for the testicular cancer can be obviously improved, and simultaneously, the administration dose, the administration time course and the side effects of the platimun-type anti-tumour medicines can be reduced. The invention also improves a molecular mechanism of the platinum-type anti-tumour medicines for treating the testicular cancer and develops a new treatment target spot for treating the testicular cancer, thereby having a significant value.
Owner:UNIV OF SCI & TECH OF CHINA

Methods and compositions for evaluation of fertility

The present invention concerns compositions and methods for evaluating fertility in humans and animals. The invention may also be used to identify reproductive cancers such as testicular cancer. In various embodiments of the invention, an Sptrx-3 enzyme is used as a fertility marker. Sptrx-3 may be detected in accordance with the invention in vitro or in vivo.
Owner:UNIVERSITY OF MISSOURI

Compounds and methods for modulation of estrogen receptors

InactiveUS7435729B2BiocideSenses disorderEccentric hypertrophyHormonal imbalance
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-β over ER-α. Methods are disclosed for modulating ER-β in cell and / or tissues expressing the same, including cells and / or tissue that preferentially express ER-β. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.
Owner:SIGNAL PHARMA LLC

Method and Kit for Determining Sensitivity to Decitabine Treatment

The present invention is a gene expression panel of chemotherapeutic drug-resistant cancer stem cells comprising RIN1, SOX15 and TLR4. In one embodiment the cancer stem cells are testicular cancer germ cells. The present invention provides for a kit and method for determining response to treatment with decitabine at low doses.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE

Compositions for Inhibiting Growth of Cancer Stem Cells

The present invention is a biomarker of chemotherapeutic drug-resistant cancer stem cells and a method of inhibiting the growth of drug-resistant cancer stem cells. In one embodiment the cancer stem cells are testicular cancer germ cells. In another embodiment the present invention is a method of overcoming drug resistance in cancer treatment where the combination of low dose decitabine and administration of a chemotherapeutic drug to which cancer cells were resistant results in successful cancer treatment.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE

Alkylsulphonamide quinolines

The invention discloses compounds of Formula (1), pharmaceutically-acceptable salts, methods of making them, pharmaceutical compositions containing them and methods for their use. The compounds are neurokinin-3(NK-3) receptor antagonists and are used in the treatment of diseases such as depression, anxiety, schizophrenia, cognitive disorders, psychoses, obesity, inflammatory diseases, irritable bowel syndrome, inflammatory bowel disorder, emesis, preeclampsia, chronic obstructive pulmonary disease, disorders associated with excessive gonadotrophins and / or androgens including dysmenorrhea, benign prostatic hyperplasia, prostatic cancer and testicular cancer.
Owner:ASTRAZENECA AB

Methods and compounds for modulating male fertility

The invention features methods and reagents useful for the treatment of excessive or insufficient apoptosis in cells, and, particularly, in germ-line cells. The invention is useful in treating testicular cancers, cancers of germ-line cells, cancers in non-germ-line cell tissues, infertility (e.g., male infertility), and for birth control (e.g., male birth control).
Owner:UNIVERSITY OF OTTAWA

Application of proguanil to preparation of anti-tumor drug

The invention discloses application of proguanil to preparation of an anti-tumor drug and application of proguanil to preparation of a drug for inhibiting primary tumor growth and / or metastatic tumorgrowth; a tumor is a malignant tumor or a benign tumor, wherein the malignant tumor comprises one or more of a bladder tumor, melanoma, mastadenoma, non-Hodgkin's lymphoma, a colorectal cancer, a pancreatic cancer, an endometrial cancer, a prostate cancer, renal carcinoma, renal cell carcinoma, a non-melanoma skin cancer, leukemia, a thyroid cancer, a lung cancer, a cervical cancer, an ovarian cancer, a testicular cancer and a central nervous system tumor; the drug is a proguanil single component or a pharmaceutical composition containing an effective dose of proguanil, a drug mixture or a molecular structure modifier. Study results show that the proguanil realizes a strong anti-cancer effect by key protein AMPK in targeting tumor cell energy metabolism, and the effect of the proguanil ontumor treatment is stronger than that of N-(4-fluorophenyl) biguanidine, metformin and other biguanidine drugs.
Owner:HUNAN NORMAL UNIVERSITY

(Arylamidoaryl)squaramide compounds

InactiveUS20060111349A1BiocideOrganic chemistryAbnormal tissue growthAdenoid cystic carcinoma
Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R5, m and J are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis / mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer / T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.
Owner:OSI PHARMA INC

Purpose of pyrazolopyrimidine derivative for preparation of medicine for treating diseases

The invention relates to the technical field of a medicine, and especially relates to a purpose of pyrazolopyrimidine derivative for preparation of medicine for treating diseases. The diseases includemyelodysplastic syndrome, ovarian cancer, testicular cancer, skin squamous cell carcinoma, bladder cancer, cancer of biliary duct, prostate cancer, glioma, nasopharyngeal carcinoma, renal cancer, tongue squamous carcinoma, squamous cell lung carcinoma, maxicell lung cancer, renal cell adenocarcinoma, choriocarcinoma, and placental villus cancer. The pyrazolopyrimidine derivative of the inventionhas obvious inhibitory effects on various tumor cells, especially the tumor cell inhibiting effect of glioma, and the inhibition effect on some tumor cells is better than that of sorafenib.
Owner:GUANGXI WUZHOU PHARMA GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products